PMID: 7539288Feb 1, 1995Paper

Serotonin, schizophrenia and antipsychotic drug action

Schizophrenia Research
A Breier

Abstract

A rapidly growing body of data suggests that dysfunction in serotonergic (5-HT) function may be involved in the pathophysiology of schizophrenia, and that pharmacologic agents for this illness have their therapeutic effects mediated through serotonergic mechanisms. The purpose of this paper is to critically review data relevant to 5-HT's role in the pathophysiology and drug treatment of schizophrenia. Pathophysiologic evidence includes the psychotomimetic effects of lysergic acid (LSD), postmortem studies, single-dose 'challenge' studies and investigations of CSF and peripheral levels of 5-HT and its metabolites. The current nomenclature, potential therapeutic effects and importance of 5-HT receptor subtype antagonism will be examined. In addition, relatively novel strategies of 5-HT uptake blockade and direct acting 5-HT agonists will be assessed. A hypothesis of cortical-subcortical imbalance with an increase in subcortical 5-HT function responsible for positive symptoms and a decrease in prefrontal 5-HT function responsible for negative symptoms is proposed. Future implications of these data are discussed.

References

Mar 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·T J CrowW S Killpack
Jan 1, 1978·Developmental Neuroscience·J M Lauder, H Krebs
Mar 9, 1978·Nature·J E LeysenP M Laduron
Aug 7, 1978·Life Sciences·A V MackayL L Iversen
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·L DemchyshynH B Niznik
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G McAllisterP Whiting
May 11, 1991·Lancet·A WhiteC Faulconbridge
Jan 1, 1991·Journal of Neural Transmission. General Section·R C Arora, H Y Meltzer
Oct 15, 1991·Biological Psychiatry·N IqbalH M van Praag
Dec 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·P J Harrison
Jan 1, 1990·Pharmacology & Toxicology·G PetterssonJ A Engel
Sep 1, 1990·The Journal of Nervous and Mental Disease·B Kirkpatrick, R W Buchanan
Jan 1, 1990·Annals of the New York Academy of Sciences·J M PalaciosG Mengod
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D JuliusT M Jessell
Jan 1, 1990·Pharmacology & Toxicology·E Christensson, A Björk
Jul 1, 1988·Brain Research Bulletin·X M Guan, W J McBride
Nov 20, 1989·Brain Research·S C CheethamG P Reynolds
Nov 1, 1989·Naunyn-Schmiedeberg's Archives of Pharmacology·C WaeberD Hoyer
Jun 19, 1989·Neuroscience Letters·A Imperato, L Angelucci
Sep 22, 1989·European Journal of Pharmacology·R A GlennonS J Peroutka
Feb 15, 1989·Biological Psychiatry·H SilverB Lerer
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S M MolineauxD Julius

❮ Previous
Next ❯

Citations

Jan 1, 1997·Journal of Neural Transmission·E SchulzH Remschmidt
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Torgny H Svensson
Sep 12, 2000·Psychiatry Research·P GovitrapongA Srikiatkhachorn
Jul 27, 2001·Psychiatry Research·A SerrettiE Smeraldi
Mar 26, 2003·Brain Research. Molecular Brain Research·Charles D NicholsElaine Sanders-Bush
Jul 11, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·Y KanedaI Nagamine
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Feb 16, 1999·Schizophrenia Research·A SerrettiE Smeraldi
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·E AngelopoulosC Stefanis
Oct 16, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·E NowakowskaJ Rybakowski
Mar 10, 2000·Epidemiologia e psichiatria sociale·P Dazzan, R M Murray
May 13, 1999·Journal of Clinical Pharmacy and Therapeutics·S AkhondzadehR Davari-Ashtiani
Nov 21, 1998·The European Journal of Neuroscience·P O TremblayC Rouillard
Mar 19, 2011·Psychiatry and Clinical Neurosciences·Makoto BannaiEiji Shimizu
Feb 10, 2011·Neuropsychobiology·Ulrich SchmittFabian Debus
Sep 14, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Eric FakraOlivier Blin
Dec 8, 2015·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Florence HagenmullerWolfram Kawohl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.